{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:08:28Z","timestamp":1794830908051,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical University of Silesia","award":["BNW-1-020\/N\/4\/K"],"award-info":[{"award-number":["BNW-1-020\/N\/4\/K"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02852-z","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:58:34Z","timestamp":1753909114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Diabetic kidney disease phenotypes and the risk of cardiovascular events: The Silesia Diabetes-Heart Project"],"prefix":"10.1186","volume":"24","author":[{"given":"Oliwia","family":"Janota-Sosi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Irlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kwiendacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olejarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Pabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"W\u0142osowicz-Momot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pia\u015bnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Szromek-Bia\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gumprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Nabrdalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2852_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 11th edn. Brussels, Belgium: 2025. Available at: https:\/\/www.diabetesatlas.org."},{"issue":"4","key":"2852_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/dme.12312","volume":"31","author":"CJ Hill","year":"2014","unstructured":"Hill CJ, Cardwell CR, Patterson CC, et al. Chronic kidney disease and diabetes in the national health service: a cross-sectional survey of the U.K. national diabetes audit. Diabet Med. 2014;31(4):448\u201354. https:\/\/doi.org\/10.1111\/dme.12312.","journal-title":"Diabet Med"},{"issue":"24","key":"2852_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus-mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459\u2013502. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022194.","journal-title":"Circulation"},{"key":"2852_CR4","doi-asserted-by":"publisher","first-page":"100739","DOI":"10.1016\/j.eclinm.2021.100739","volume":"32","author":"CA Lawson","year":"2021","unstructured":"Lawson CA, Seidu S, Zaccardi F, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021;32:100739. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100739.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2852_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI17867","volume":"114","author":"CB Renard","year":"2004","unstructured":"Renard CB, Kramer F, Johansson F, et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 2004;114(5):659\u201368. https:\/\/doi.org\/10.1172\/JCI17867.","journal-title":"J Clin Invest"},{"issue":"20","key":"2852_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636\u201364. https:\/\/doi.org\/10.1161\/CIR.0000000000001186.","journal-title":"Circulation"},{"issue":"1","key":"2852_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00125-008-1190-x","volume":"52","author":"K Eeg-Olofsson","year":"2009","unstructured":"Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65\u201373. https:\/\/doi.org\/10.1007\/s00125-008-1190-x.","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"2852_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/diab.32.2.s64","volume":"32","author":"CE Mogensen","year":"1983","unstructured":"Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64\u201378. https:\/\/doi.org\/10.2337\/diab.32.2.s64.","journal-title":"Diabetes"},{"issue":"8","key":"2852_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2337\/dc08-2186","volume":"32","author":"MC Thomas","year":"2009","unstructured":"Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32(8):1497\u2013502. https:\/\/doi.org\/10.2337\/dc08-2186.","journal-title":"Diabetes Care"},{"issue":"10","key":"2852_CR10","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2337\/dc19-0349","volume":"42","author":"D Vistisen","year":"2019","unstructured":"Vistisen D, Andersen GS, Hulman A, Persson F, Rossing P, J\u00f8rgensen ME. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria. Diabetes Care. 2019;42(10):1886\u201394. https:\/\/doi.org\/10.2337\/dc19-0349.","journal-title":"Diabetes Care"},{"issue":"1","key":"2852_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2337\/dc13-0985","volume":"37","author":"AS Krolewski","year":"2014","unstructured":"Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37(1):226\u201334. https:\/\/doi.org\/10.2337\/dc13-0985.","journal-title":"Diabetes Care"},{"issue":"6","key":"2852_CR12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00125-017-4251-1","volume":"60","author":"G Penno","year":"2017","unstructured":"Penno G, Russo E, Garofolo M, et al. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia. 2017;60(6):1102\u201313. https:\/\/doi.org\/10.1007\/s00125-017-4251-1.","journal-title":"Diabetologia"},{"issue":"2","key":"2852_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamacardio.2017.4228","volume":"3","author":"BM Scirica","year":"2018","unstructured":"Scirica BM, Mosenzon O, Bhatt DL, et al. Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial. JAMA Cardiol. 2018;3(2):155\u201363. https:\/\/doi.org\/10.1001\/jamacardio.2017.4228.","journal-title":"JAMA Cardiol"},{"key":"2852_CR14","doi-asserted-by":"publisher","first-page":"977938","DOI":"10.3389\/fcvm.2022.977938","volume":"9","author":"CS Sheng","year":"2022","unstructured":"Sheng CS, Wang D, Yuan J, et al. CVD risk in non-albuminuric chronic kidney disease in hypertensive, non-diabetic subjects: a post-hoc analysis from SPRINT. Front Cardiovasc Med. 2022;9:977938. https:\/\/doi.org\/10.3389\/fcvm.2022.977938.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"2852_CR15","doi-asserted-by":"publisher","first-page":"e0283083","DOI":"10.1371\/journal.pone.0283083","volume":"18","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Hwang SW, Lee T, Lee JY, Uh Y. Association between urinary albumin creatinine ratio and cardiovascular disease. PLoS ONE. 2023;18(3):e0283083. https:\/\/doi.org\/10.1371\/journal.pone.0283083.","journal-title":"PLoS ONE"},{"issue":"21","key":"2852_CR16","doi-asserted-by":"publisher","first-page":"e026685","DOI":"10.1161\/JAHA.122.026685","volume":"11","author":"Y Choi","year":"2022","unstructured":"Choi Y, Jacobs DR Jr, Shroff GR, Kramer H, Chang AR, Duprez DA. Progression of chronic kidney disease risk categories and risk of cardiovascular disease and total mortality: coronary artery risk development in young adults cohort. J Am Heart Assoc. 2022;11(21):e026685. https:\/\/doi.org\/10.1161\/JAHA.122.026685.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2852_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/dc19-2049","volume":"43","author":"H Yokoyama","year":"2020","unstructured":"Yokoyama H, Araki SI, Kawai K, et al. The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM 54). Diabetes Care. 2020;43(5):1102\u201310. https:\/\/doi.org\/10.2337\/dc19-2049.","journal-title":"Diabetes Care"},{"issue":"7","key":"2852_CR18","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.cpcardiol.2023.101694","volume":"48","author":"K Nabrdalik","year":"2023","unstructured":"Nabrdalik K, Kwiendacz H, Dro\u017cd\u017c K, et al. Machine learning predicts cardiovascular events in patients with diabetes: the Silesia Diabetes-Heart project. Curr Probl Cardiol. 2023;48(7):101694. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101694.","journal-title":"Curr Probl Cardiol"},{"key":"2852_CR19","unstructured":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease [Internet]. Available from: www.kidney-international.org"},{"issue":"1","key":"2852_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12933-023-01867-8","volume":"22","author":"DH Kofod","year":"2023","unstructured":"Kofod DH, Carlson N, Ballegaard EF, et al. Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2023;22(1):140. https:\/\/doi.org\/10.1186\/s12933-023-01867-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2852_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-021-01279-6","volume":"20","author":"CT Chao","year":"2021","unstructured":"Chao CT, Lee SY, Wang J, Chien KL, Hung KY. The risk trajectory of different cardiovascular morbidities associated with chronic kidney disease among patients with newly diagnosed diabetes mellitus: a propensity score-matched cohort analysis. Cardiovasc Diabetol. 2021;20(1):86. https:\/\/doi.org\/10.1186\/s12933-021-01279-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"2852_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/toxins10090367","volume":"10","author":"WC Liu","year":"2018","unstructured":"Liu WC, Tomino Y, Lu KC. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120. Toxins (Basel). 2018;10(9):367. https:\/\/doi.org\/10.3390\/toxins10090367.","journal-title":"Toxins (Basel)"},{"issue":"1","key":"2852_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/ijms23010531","volume":"23","author":"E Harlacher","year":"2022","unstructured":"Harlacher E, Wollenhaupt J, Baaten CCFMJ, Noels H. Impact of uremic toxins on endothelial dysfunction in chronic kidney disease: a systematic review. Int J Mol Sci. 2022;23(1):531. https:\/\/doi.org\/10.3390\/ijms23010531.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2852_CR24","doi-asserted-by":"publisher","first-page":"e065927","DOI":"10.1136\/bmjopen-2022-065927","volume":"13","author":"S Cook","year":"2023","unstructured":"Cook S, Schmedt N, Broughton J, Kalra PA, Tomlinson LA, Quint JK. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the clinical practice research datalink. BMJ Open. 2023;13(3):e065927. https:\/\/doi.org\/10.1136\/bmjopen-2022-065927.","journal-title":"BMJ Open"},{"issue":"8","key":"2852_CR25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2215\/CJN.13111215","volume":"11","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Katz R, Bansal N, et al. Diabetes, kidney disease, and cardiovascular outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol. 2016;11(8):1384\u201391. https:\/\/doi.org\/10.2215\/CJN.13111215.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2852_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/biom13050752","volume":"13","author":"S Scilletta","year":"2023","unstructured":"Scilletta S, Di Marco M, Miano N, et al. Update on diabetic kidney disease (DKD): focus on non-albuminuric DKD and cardiovascular risk. Biomolecules. 2023;13(5):752. https:\/\/doi.org\/10.3390\/biom13050752.","journal-title":"Biomolecules"},{"issue":"8","key":"2852_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/ASN.2008121270","volume":"20","author":"T Ninomiya","year":"2009","unstructured":"Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813\u201321. https:\/\/doi.org\/10.1681\/ASN.2008121270.","journal-title":"J Am Soc Nephrol"},{"key":"2852_CR28","doi-asserted-by":"publisher","unstructured":"Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbj\u00f6rnsdottir S; Swedish National Diabetes Register. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res. 2013;10(6):520\u20139. https:\/\/doi.org\/10.1177\/14791641135007","DOI":"10.1177\/14791641135007"},{"issue":"1","key":"2852_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00125-010-1854-1","volume":"54","author":"PL Drury","year":"2011","unstructured":"Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54(1):32\u201343. https:\/\/doi.org\/10.1007\/s00125-010-1854-1.","journal-title":"Diabetologia"},{"issue":"11","key":"2852_CR30","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00125-018-4691-2","volume":"61","author":"G Penno","year":"2018","unstructured":"Penno G, Solini A, Orsi E, et al. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia. 2018;61(11):2277\u201389. https:\/\/doi.org\/10.1007\/s00125-018-4691-2.","journal-title":"Diabetologia"},{"issue":"1","key":"2852_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12933-023-02065-2","volume":"22","author":"M Di Marco","year":"2023","unstructured":"Di Marco M, Scilletta S, Miano N, et al. Cardiovascular risk and renal injury profile in subjects with type 2 diabetes and non-albuminuric diabetic kidney disease. Cardiovasc Diabetol. 2023;22(1):344. https:\/\/doi.org\/10.1186\/s12933-023-02065-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"2852_CR32","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","volume":"289","author":"HJ Kramer","year":"2003","unstructured":"Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273\u20137. https:\/\/doi.org\/10.1001\/jama.289.24.3273.","journal-title":"JAMA"},{"key":"2852_CR33","doi-asserted-by":"publisher","first-page":"871272","DOI":"10.3389\/fendo.2022.871272","volume":"13","author":"S Shi","year":"2022","unstructured":"Shi S, Ni L, Gao L, Wu X. Comparison of nonalbuminuric and albuminuric diabetic kidney disease among patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:871272. https:\/\/doi.org\/10.3389\/fendo.2022.871272.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2852_CR34","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","volume":"19","author":"P Gaede","year":"2004","unstructured":"Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transpl. 2004;19(11):2784\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfh470.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"2852_CR35","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309\u201320. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00653.x.","journal-title":"Kidney Int"},{"issue":"2","key":"2852_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.ajkd.2021.11.011","volume":"80","author":"Q Jin","year":"2022","unstructured":"Jin Q, Luk AO, Lau ESH, et al. Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes: findings from the Hong Kong Diabetes Biobank. Am J Kidney Dis. 2022;80(2):196-206.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2021.11.011.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2852_CR37","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"11","key":"2852_CR38","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P G\u00e6de","year":"2016","unstructured":"G\u00e6de P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298\u2013307. https:\/\/doi.org\/10.1007\/s00125-016-4065-6.","journal-title":"Diabetologia"},{"issue":"22","key":"2852_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"2","key":"2852_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"4","key":"2852_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"15","key":"2852_CR42","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"2852_CR43","unstructured":"KDIGO 2020 Clinical practice guideline for the evaluation and management of chronic kidney disease [Internet]. Available from: www.kidney-international.org."},{"key":"2852_CR44","unstructured":"KDIGO 2022 Clinical practice guideline for the evaluation and management of chronic kidney disease [Internet]. Available from: www.kidney-international.org."},{"key":"2852_CR45","unstructured":"Summary of Product Characteristics FARXIGA\u00ae (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014 [Internet]. Available from: https:\/\/www.fda.gov\/drugsatfda."},{"key":"2852_CR46","unstructured":"Summary of Product Characteristics JARDIANCE\u00ae (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014 [Internet]. Available from: https:\/\/www.fda.gov\/drugsatfda."},{"issue":"22","key":"2852_CR47","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387(22):2021\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2210639.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02852-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02852-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02852-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:58:37Z","timestamp":1753909117000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02852-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2852"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02852-z","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Based on the decision of the Bioethics Committee of the Medical University of Silesia in Katowice, the need for ethical approval was waived (decision no. PCN\/0022\/KB\/126\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for the publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}